Evidence map›Paper›PMID 28960867›Full record

Trial reportESC heart failure2017

Clinical presentation at first heart failure hospitalization does not predict recurrent heart failure admission.

Annamaria Kosztin, Jason Costa, Arthur J Moss, Yitschak Biton, Vivien Klaudia Nagy, Scott D Solomon, Laszlo Geller, Scott McNitt, Bronislava Polonsky, Bela Merkely and 1 more

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in ESC heart failure, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Annamaria KosztinSemmelweis University, Budapest, Hungary.
Jason CostaHeart Research Follow-Up Program, University of Rochester Medical Center, Rochester, NY, USA.
Arthur J MossHeart Research Follow-Up Program, University of Rochester Medical Center, Rochester, NY, USA.
Yitschak BitonHeart Research Follow-Up Program, University of Rochester Medical Center, Rochester, NY, USA.
Vivien Klaudia NagySemmelweis University, Budapest, Hungary.
Scott D SolomonBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Laszlo GellerSemmelweis University, Budapest, Hungary.
Scott McNittHeart Research Follow-Up Program, University of Rochester Medical Center, Rochester, NY, USA.
Bronislava PolonskyHeart Research Follow-Up Program, University of Rochester Medical Center, Rochester, NY, USA.
Bela MerkelySemmelweis University, Budapest, Hungary.
Valentina KutyifaHeart Research Follow-Up Program, University of Rochester Medical Center, Rochester, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThere are limited data on whether clinical presentation at first heart failure (HF) hospitalization predicts recurrent HF events. We aimed to assess predictors of recurrent HF hospitalizations in mild HF patients with an implantable cardioverter defibrillator or cardiac resynchronization therapy with defibrillator. METHODS AND

resultsData on HF hospitalizations were prospectively collected for patients enrolled in MADIT-CRT. Predictors of recurrent HF hospitalization (HF2) after the first HF hospitalization were assessed using Cox proportional hazards regression models including baseline covariates and clinical presentation or management at first HF hospitalization. There were 193 patients with first HF hospitalization, and 156 patients with recurrent HF events. Recurrent HF rate after the first HF hospitalization was 43% at 1 year, 52% at 2 years, and 55% at 2.5 years. Clinical signs and symptoms, medical treatment, or clinical management of HF at first HF admission was not predictive for HF2. Baseline covariates predicting recurrent HF hospitalization included prior HF hospitalization (HR = 1.59, 95% CI: 1.15-2.20, P = 0.005), digitalis therapy (HR = 1.58, 95% CI: 1.13-2.20, P = 0.008), and left ventricular end-diastolic volume >240 mL (HR = 1.62, 95% CI: 1.17-2.25, P = 0.004).

conclusionsRecurrent HF events are frequent following the first HF hospitalization in patients with implanted implantable cardioverter defibrillator or cardiac resynchronization therapy with defibrillator. Neither clinical presentation nor clinical management during first HF admission was predictive of recurrent HF. Prior HF hospitalization, digitalis therapy, and left ventricular end-diastolic volume at enrolment predicted recurrent HF hospitalization, and these covariates could be used as surrogate markers for identifying a high-risk cohort.

Indexed as

Cardiac Resynchronization TherapyRisk AssessmentAgedFemaleHeart FailureHospitalizationHumansMalePatient ReadmissionPrognosisProspective StudiesRecurrenceRisk FactorsSurvival RateUnited StatesCardiac resynchronization therapyHeart failure hospitalizationRecurrent hospitalization

Identifiers

PMID28960867
PMCPMC5695168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.